Skip to main content
MicroPort CardioFlow Medtech Corporation logo

MicroPort CardioFlow Medtech Corporation — Investor Relations & Filings

Ticker · 2160 ISIN · KYG6082P1138 LEI · 254900V03B971A7FK886 HKEX Manufacturing
Open in API
Filings indexed 293 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2160

About MicroPort CardioFlow Medtech Corporation

http://www.cardioflowmedtech.com

MicroPort CardioFlow Medtech Corporation develops and commercializes innovative transcatheter and surgical solutions for structural heart intervention and cardiac rhythm management. The core business focuses on treating valvular heart diseases (aortic and mitral) and left atrial appendage occlusion. Key commercialized products include the VitaFlow Liberty® TAVI system, recognized globally as the only electric recoverable transcatheter aortic valve implantation device, and the AnchorMan® Left Atrial Appendage Occluder System, which holds dual NMPA and CE MDR approvals. Following the strategic merger with MicroPort CRM in late 2025, the company expanded its scope to build a global heart failure treatment platform, driving international commercialization of its portfolio across major global markets.

Recent filings

Filing Released Lang Actions
2025 Annual Report
Regulatory Filings
2026-04-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is an HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” filed under the Exchange Listing Rules, detailing monthly movements in authorised/issued share capital, share options, confirmations under listing rules, etc. This is a recurring regulatory compliance return rather than a financial report (10-K, IR, ER) or an announcement of a specific transaction (e.g., SHA or POS) or management presentation. It does not itself propose a new share issue or merger, but provides regulatory reporting of share movements. Therefore it falls under the general “Regulatory Filings” category (RNS).
2026-04-09 English
CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE 2026 DISTRIBUTION AGREEMENTS
Regulatory Filings Classification · 1% confidence The document is a Hong Kong stock exchange announcement detailing "Continuing Connected Transactions" under Chapter 14A of the Listing Rules, including framework agreements, annual caps, pricing policies, and historical transaction amounts. It is not a financial report (10-K, IR, ER), not an AGM or proxy statement, and not a director/share issue notice. Rather, it is a standalone regulatory announcement of ongoing related-party transactions. This fits the fallback category “Regulatory Filings (RNS)” for miscellaneous regulatory announcements.
2026-04-08 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 1% confidence The document is titled “ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025” and contains the audited consolidated results overview, financial summary, and business review narrative. It is the initial stock exchange announcement of the annual financial results rather than the full Annual Report (10-K) or statutory filing. Therefore, it matches the definition of an Earnings Release (ER). FY 2025
2026-04-02 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 1% confidence The document is a Hong Kong stock exchange announcement titled “Annual Results Announcement for the Year Ended December 31, 2025” with an audited consolidated results summary, key financial highlights in tabular form, and a business review narrative. It does not contain the full annual report or detailed statutory financial statements but provides an initial release of the period’s financial results and operational commentary. This matches the definition of an Earnings Release. FY 2025
2026-03-30 English
CHANGE OF PRESENTATION CURRENCY
Regulatory Filings Classification · 1% confidence The document is an official announcement from MicroPort CardioFlow Medtech Corporation regarding a change in the presentation currency for its consolidated financial statements from RMB to USD. It does not contain financial statements, nor is it a report publication announcement, but rather a specific corporate disclosure regarding accounting policy changes. As it does not fit into specific categories like M&A, dividends, or director dealings, it falls under the general regulatory announcement category.
2026-03-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.